+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Global Cystic Fibrosis Market by Drug Class (Bronchodilators, CFTR Modulators, Mucolytics), Route of Administration (Inhaled Drugs, Oral Drugs) - Forecast 2024-2030- Product Image
Global Cystic Fibrosis Market by Drug Class (Bronchodilators, CFTR Modulators, Mucolytics), Route of Administration (Inhaled Drugs, Oral Drugs) - Forecast 2024-2030- Product Image
Sale

Global Cystic Fibrosis Market by Drug Class (Bronchodilators, CFTR Modulators, Mucolytics), Route of Administration (Inhaled Drugs, Oral Drugs) - Forecast 2024-2030

  • PDF Icon

    Report

  • 184 Pages
  • March 2024
  • Region: Global
  • 360iResearch™
  • ID: 4829814
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Cystic Fibrosis Market size was estimated at USD 5.88 billion in 2023, USD 6.44 billion in 2024, and is expected to grow at a CAGR of 9.53% to reach USD 11.13 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Cystic Fibrosis Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Cystic Fibrosis Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Cystic Fibrosis Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Alcresta Therapeutics, Inc., AlgiPharma AS, AstraZeneca PLC, CHIESI Farmaceutici S.p.A., Elucigene Diagnostics by Delta Diagnostics (UK) Limited, F. Hoffmann-La Roche AG, Galapagos NV, Gilead Sciences, Inc., Johnson & Johnson Services, Inc., NovaBiotics Ltd., Novartis AG, Pharmaxis Ltd., PTC Therapeutics, Inc., and Vertex Pharmaceuticals Incorporated.

Market Segmentation & Coverage

This research report categorizes the Cystic Fibrosis Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Drug Class
    • Bronchodilators
    • CFTR Modulators
    • Mucolytics
    • Pancreatic Enzyme Supplements
  • Route of Administration
    • Inhaled Drugs
    • Oral Drugs
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as

  1. What is the market size and forecast of the Cystic Fibrosis Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Cystic Fibrosis Market?
  3. What are the technology trends and regulatory frameworks in the Cystic Fibrosis Market?
  4. What is the market share of the leading vendors in the Cystic Fibrosis Market?
  5. Which modes and strategic moves are suitable for entering the Cystic Fibrosis Market?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Cystic Fibrosis Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising prevalence of Cystic Fibrosis & improved diagnostic technologies
5.1.1.2. Increasing global awareness for Cystic Fibrosis
5.1.1.3. Favorable initiatives are taken by NGOs, government, and private companies
5.1.2. Restraints
5.1.2.1. Expiring patents and generic drugs
5.1.2.2. Increase in genetic mutation rate
5.1.3. Opportunities
5.1.3.1. Research & development activities and robust drug development pipeline
5.1.3.2. Growing strategic collaborations, merger, and acquisition
5.1.4. Challenges
5.1.4.1. High cost involved in treatment and complicated pathophysiology
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Cystic Fibrosis Market, by Drug Class
6.1. Introduction
6.2. Bronchodilators
6.3. CFTR Modulators
6.4. Mucolytics
6.5. Pancreatic Enzyme Supplements
7. Cystic Fibrosis Market, by Route of Administration
7.1. Introduction
7.2. Inhaled Drugs
7.3. Oral Drugs
8. Americas Cystic Fibrosis Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. Asia-Pacific Cystic Fibrosis Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam
10. Europe, Middle East & Africa Cystic Fibrosis Market
10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom
11. Competitive Landscape
11.1. FPNV Positioning Matrix
11.2. Market Share Analysis, By Key Player
11.3. Competitive Scenario Analysis, By Key Player
12. Competitive Portfolio
12.1. Key Company Profiles
12.1.1. AbbVie Inc.
12.1.2. Alcresta Therapeutics, Inc.
12.1.3. AlgiPharma AS
12.1.4. AstraZeneca PLC
12.1.5. CHIESI Farmaceutici S.p.A.
12.1.6. Elucigene Diagnostics by Delta Diagnostics (UK) Limited
12.1.7. F. Hoffmann-La Roche AG
12.1.8. Galapagos NV
12.1.9. Gilead Sciences, Inc.
12.1.10. Johnson & Johnson Services, Inc.
12.1.11. NovaBiotics Ltd.
12.1.12. Novartis AG
12.1.13. Pharmaxis Ltd.
12.1.14. PTC Therapeutics, Inc.
12.1.15. Vertex Pharmaceuticals Incorporated
12.2. Key Product Portfolio
13. Appendix
13.1. Discussion Guide
13.2. License & Pricing
List of Figures
FIGURE 1. CYSTIC FIBROSIS MARKET RESEARCH PROCESS
FIGURE 2. CYSTIC FIBROSIS MARKET SIZE, 2023 VS 2030
FIGURE 3. CYSTIC FIBROSIS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. CYSTIC FIBROSIS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. CYSTIC FIBROSIS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. CYSTIC FIBROSIS MARKET DYNAMICS
FIGURE 7. CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
FIGURE 8. CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 10. CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. AMERICAS CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 12. AMERICAS CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. UNITED STATES CYSTIC FIBROSIS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 14. UNITED STATES CYSTIC FIBROSIS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. ASIA-PACIFIC CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 16. ASIA-PACIFIC CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. CYSTIC FIBROSIS MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 20. CYSTIC FIBROSIS MARKET SHARE, BY KEY PLAYER, 2023
List of Tables
TABLE 1. CYSTIC FIBROSIS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. CYSTIC FIBROSIS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 6. CYSTIC FIBROSIS MARKET SIZE, BY BRONCHODILATORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. CYSTIC FIBROSIS MARKET SIZE, BY MUCOLYTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. CYSTIC FIBROSIS MARKET SIZE, BY PANCREATIC ENZYME SUPPLEMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 11. CYSTIC FIBROSIS MARKET SIZE, BY INHALED DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. CYSTIC FIBROSIS MARKET SIZE, BY ORAL DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. AMERICAS CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 14. AMERICAS CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 15. AMERICAS CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 16. ARGENTINA CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 17. ARGENTINA CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 18. BRAZIL CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 19. BRAZIL CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 20. CANADA CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 21. CANADA CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 22. MEXICO CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 23. MEXICO CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 24. UNITED STATES CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 25. UNITED STATES CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 26. UNITED STATES CYSTIC FIBROSIS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 27. ASIA-PACIFIC CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 28. ASIA-PACIFIC CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 29. ASIA-PACIFIC CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 30. AUSTRALIA CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 31. AUSTRALIA CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 32. CHINA CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 33. CHINA CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 34. INDIA CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 35. INDIA CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 36. INDONESIA CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 37. INDONESIA CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 38. JAPAN CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 39. JAPAN CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 40. MALAYSIA CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 41. MALAYSIA CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 42. PHILIPPINES CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 43. PHILIPPINES CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 44. SINGAPORE CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 45. SINGAPORE CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 46. SOUTH KOREA CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 47. SOUTH KOREA CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 48. TAIWAN CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 49. TAIWAN CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 50. THAILAND CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 51. THAILAND CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 52. VIETNAM CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 53. VIETNAM CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 54. EUROPE, MIDDLE EAST & AFRICA CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 55. EUROPE, MIDDLE EAST & AFRICA CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 56. EUROPE, MIDDLE EAST & AFRICA CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 57. DENMARK CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 58. DENMARK CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 59. EGYPT CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 60. EGYPT CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 61. FINLAND CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 62. FINLAND CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 63. FRANCE CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 64. FRANCE CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 65. GERMANY CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 66. GERMANY CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 67. ISRAEL CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 68. ISRAEL CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 69. ITALY CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 70. ITALY CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 71. NETHERLANDS CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 72. NETHERLANDS CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 73. NIGERIA CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 74. NIGERIA CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 75. NORWAY CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 76. NORWAY CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 77. POLAND CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 78. POLAND CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 79. QATAR CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 80. QATAR CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 81. RUSSIA CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 82. RUSSIA CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 83. SAUDI ARABIA CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 84. SAUDI ARABIA CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 85. SOUTH AFRICA CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 86. SOUTH AFRICA CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 87. SPAIN CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 88. SPAIN CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 89. SWEDEN CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 90. SWEDEN CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 91. SWITZERLAND CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 92. SWITZERLAND CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 93. TURKEY CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 94. TURKEY CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 95. UNITED ARAB EMIRATES CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 96. UNITED ARAB EMIRATES CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 97. UNITED KINGDOM CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 98. UNITED KINGDOM CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 99. CYSTIC FIBROSIS MARKET, FPNV POSITIONING MATRIX, 2023
TABLE 100. CYSTIC FIBROSIS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 101. CYSTIC FIBROSIS MARKET LICENSE & PRICING

Companies Mentioned

  • AbbVie Inc.
  • Alcresta Therapeutics, Inc.
  • AlgiPharma AS
  • AstraZeneca PLC
  • CHIESI Farmaceutici S.p.A.
  • Elucigene Diagnostics by Delta Diagnostics (UK) Limited
  • F. Hoffmann-La Roche AG
  • Galapagos NV
  • Gilead Sciences, Inc.
  • Johnson & Johnson Services, Inc.
  • NovaBiotics Ltd.
  • Novartis AG
  • Pharmaxis Ltd.
  • PTC Therapeutics, Inc.
  • Vertex Pharmaceuticals Incorporated

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages184
PublishedMarch 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 6.44 Billion
Forecasted Market Value ( USD ) by 2030 $ 11.13 Billion
Compound Annual Growth Rate9.5%
Regions CoveredGlobal
No. of Companies Mentioned15

Related Topics

Related Reports

Global Cystic Fibrosis Market Analysis & Forecast to 2024-2034 - Product Image

Global Cystic Fibrosis Market Analysis & Forecast to 2024-2034

  • Report
  • 200 Pages
  • Global
From
Cystic Fibrosis (CF) Therapeutics Global Market Report 2024 - Product Image

Cystic Fibrosis (CF) Therapeutics Global Market Report 2024

  • Report
  • 200 Pages
  • Global
From
Cystic Fibrosis Therapeutics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028 - Product Image

Cystic Fibrosis Therapeutics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

  • Report
  • 140 Pages
  • Global
From
Global Cystic Fibrosis Treatment Market Report and Forecast 2023-2031 - Product Image

Global Cystic Fibrosis Treatment Market Report and Forecast 2023-2031

  • Report
  • 160 Pages
  • Global
From
Cystic Fibrosis Market - Forecasts from 2024 to 2029 - Product Image

Cystic Fibrosis Market - Forecasts from 2024 to 2029

  • Report
  • 145 Pages
  • Global
From

About the Cystic Fibrosis Drug Market

The Cystic Fibrosis Drug market is a subset of the larger Respiratory Drug market. It is composed of treatments and therapies designed to address the symptoms of cystic fibrosis, a genetic disorder that affects the lungs and digestive system. These drugs are used to reduce the amount of mucus in the lungs, improve breathing, and reduce the risk of infection. They may also be used to treat other symptoms, such as malnutrition, dehydration, and vitamin deficiencies. The Cystic Fibrosis Drug market is highly competitive, with many companies developing and marketing treatments. Some of the major players in the market include Vertex Pharmaceuticals, Gilead Sciences, Novartis, and GlaxoSmithKline. Other companies, such as AbbVie, Merck, and Pfizer, are also active in the market. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.